How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer Doudna
Gene-editing technology CRISPR reached a major milestone, completing its first systemic delivery as a medicine to a human body. CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.
Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, “One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”
“It’s largely because the technology comes at a moment when there’s enormous demand for genome editing, as well as a lot of knowledge about genomes,” Doudna said at the recent CNBC Global Evolve Summit in mid-June.
Read the full article here.
20 Sep 2021gMendel is giving an interactive presentation about transforming the diagnosis of genetic disorders at the SKEL | The AI Lab, Athens
23 Jul 2021Scientists report first clinical data showing that CRISPR gene editing can be done safely inside the body.
23 Jul 2021How CRISPR gene editing will treat diseases in future: Interview by Nobel-winner Intellia Jennifer Doudna.
08 Jul 2021Scientists in Australia have adapted AI technology for the early detection of prostate cancer within seconds.